Vigil Neuroscience (NASDAQ:VIGL) on Thursday said the company remains on track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024. Extends projected cash runway into second half of 2025.

Vigil Neuroscience（纳斯达克股票代码：VIGL）周四表示，该公司仍在按计划报告2024年年中健康志愿者中VG-3927的中期第一阶段数据，以及2024年第三季度在ALSP评估iluzanebart的IGNITE临床试验的第二阶段结果。将预计的现金跑道延长至2025年下半年。

Company to present at J.P. Morgan Healthcare Conference on January 11, 2024 at 7:30 a.m. PT/10:30 a.m. ET. Source: Press Release More on Vigil Neuroscience Vigil Neuroscience: Interim Data Sheds Light On Possible Accelerated Pathway Vigil Neuroscience reports interim Phase 2 data for ALSP drug candidate Vigil Neuroscience GAAP EPS of -$0.53 beats by $0.03 .

该公司将于2024年1月11日上午7:30（美国东部时间上午10:30）出席摩根大通（J.P.Morgan）医疗保健会议。来源：关于Vigil Neuroscience的更多新闻稿Vigil Neuroscience：中期数据揭示了可能的加速途径Vigil Neuroscience报告了ALSP候选药物Vigil Neuroscience GAAP EPS的中期2期数据-比0.03美元低0.53美元。